FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antibodies topics
Antibodies
Recombinant
Nucleic Acid
Nucleic Acids
Polypeptide
Therapeutics
Immunoglobulin
Immunoglobulins
Monoclonal
Radiation Therapy
Desmoplastic
Hypertension
Hypertensive
Immunotherapy
Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antibodies patents



      
           
This page is updated frequently with new Antibodies-related patent applications. Subscribe to the Antibodies RSS feed to automatically get the update: related Antibodies RSS feeds. RSS updates for this page: Antibodies RSS RSS


Human lambda light chain mice

Regeneron Pharmaceuticals

Human lambda light chain mice

Human lambda light chain mice

Regents Of University Of Michigan

Materials and methods for eliciting targeted antibody responses in vivo

Date/App# patent app List of recent Antibodies-related patents
06/25/15
20150177249
 Method and a kit for the in vitro diagnosis of pancreatic ductal adenocarcinoma or for determining the predisposition to pancreatic ductal adenocarcinoma patent thumbnailnew patent Method and a kit for the in vitro diagnosis of pancreatic ductal adenocarcinoma or for determining the predisposition to pancreatic ductal adenocarcinoma
An in vitro assay for pancreatic ductal adenocarcinoma, preferably an immunoassay, is based on the determination of anti-ezrin auto-antibodies in a biological sample from a subject suspected of being affected by pancreatic ductal adenocarcinoma or from a subject whose predisposition to pancreatic ductal adenocarcinoma one desires a determination.. .
Natimab Therapeutics S.r.l.
06/25/15
20150177242
 Combination hepatitis c virus antigen and antibody detection method patent thumbnailnew patent Combination hepatitis c virus antigen and antibody detection method
An in vitro method that allows detection of hepatitis c by detecting hepatitis c virus (hcv) core protein and antibodies to hcv core protein (anti-core antibodies) in a single assay is provided. Cross-reactivity is eliminated in the method preferably by utilizing short peptides, each of which has an amino acid sequence that corresponds to an immunodominant region of the native core protein but which does not wholly encompass the epitope bound by the antibodies utilized in the method.
Abbott Laboratories
06/25/15
20150177240
 Nogo receptor binding protein patent thumbnailnew patent Nogo receptor binding protein
The invention provides sp35 polypeptides and fusion proteins thereof, sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such sp35 antibodies, antigen-binding fragments thereof, sp35 polypeptides and fusion proteins thereof..
Biogen Idec Ma Inc.
06/25/15
20150177199
 Method and  characterizing impurity profile of organic materials patent thumbnailnew patent Method and characterizing impurity profile of organic materials
Method and apparatus for characterizing drug-modified polymers, macromolecules, proteins, antigens, antibodies or nanoparticles and quantitative determination of their impurity profile by two-dimensional liquid chromatography analysis. The first dimension is preferably size exclusion chromatography (sec)—which is also known as gel permeation chromatography in case of non-aqueous samples (gpc)—for complete molecular weight analysis of nanoscale particles.
Bbs Nanotechnology Ltd.
06/25/15
20150176002
 Human lambda light chain mice patent thumbnailnew patent Human lambda light chain mice
Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.
06/25/15
20150175711
 Anti-cd22 anti-idiotypic antibodies and uses thereof patent thumbnailnew patent Anti-cd22 anti-idiotypic antibodies and uses thereof
The present invention describes the generation of an anti-idiotype single-chain fv (scfv) antibody specific for the murine (rfb4), chimeric (sm03) and humanized (sm06) versions of an anti-cd22 antibody (the anti-cd22 antibodies). The present invention further describes the construction of a murine igg2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scfv sequences.
Sinomab Bioscience Limited
06/25/15
20150175710
 Alpha-enolase specific antibodies and  use in immune diseases patent thumbnailnew patent Alpha-enolase specific antibodies and use in immune diseases
A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against eno1. The antagonist binds eno1 and inhibits eno1 plasminogen receptor activity.
Development Center For Biotechnology
06/25/15
20150175709
 Inotropic antibodies and therapeutic uses thereof patent thumbnailnew patent Inotropic antibodies and therapeutic uses thereof
antibodies binding to sites on the alpha-subunit of the (na++k+)-atpase increase cardiac contraction of both ventricular myocytes and mouse heart. In particular, antibodies binding to the rsateeeppndd (seq id no: 1) or dvedsygqqwtyeqr (seq id no: 2) peptides (or isoforms/derivatives thereof) of the alpha-subunit of the (na++k+)-atpase, have been found to be highly inotropic.
06/25/15
20150175708
 Multifunctional antibodies binding to egfr and met patent thumbnailnew patent Multifunctional antibodies binding to egfr and met
Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (egfr) and met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by egfr and met.. .
Eli Lilly And Company
06/25/15
20150175706
 Novel antibodies against cancer target block tumor growth, angiogenesis and metastatis patent thumbnailnew patent Novel antibodies against cancer target block tumor growth, angiogenesis and metastatis
The present invention provides antibodies that target the first-third domains of n-cadherein and the fourth domain of n-cadherin, for diagnosis and therapy of cancers related to n-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described..
The Regents Of The University Of California
06/25/15
20150175705
new patent

Prlr-specific antibody and uses thereof


Prlr-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.. .
Novartis Ag
06/25/15
20150175704
new patent

Anti-nr10 antibody and use thereof


The present inventors successfully obtained anti-nr10 antibodies having an effective neutralizing activity against nr10. The anti-nr10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases..
Chugai Seiyaku Kabushiki Kaisha
06/25/15
20150175702
new patent

B7 family member zb7h6 and related compositions and methods


Disclosed is a newly identified b7 family member, zb7h6, which functions as a counter-receptor for the nk cell triggering receptor, nkp30. Methods and compositions for modulating nkp30-mediated nk cell activity based on the interaction of zb7h6 with nkp30, as well as related screening methods, are also disclosed.
Zymogenetics, Inc.
06/25/15
20150175701
new patent

Ovr110 antibody compositions and methods of use


Isolated antibodies and antigen binding fragments thereof directed against ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an ovr110-expressing cancer cells and alleviating or treating an ovr110-expressing cancer in a mammal.
Diadexus, Inc.
06/25/15
20150175699
new patent

Humanized antibodies to cluster of differentiation 3 (cd3)


Humanized monoclonal antibodies (mabs) or fragments thereof, to human cluster of differentiation 3 (cd3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mabs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to cd3, are also disclosed..
Therapix Biosciences Ltd.
06/25/15
20150175698
new patent

Recombinant antibody compositions and methods of use thereof


Provided are methods and composition useful in isolating or otherwise preparing a population of target cells. In part, it relates to recombinant antibodies comprising an exogenous proteolytic cleavage site and nucleic acid molecules encoding the antibodies..
Life Technologies As
06/25/15
20150175696
new patent

Antibodies against human csf-1r and uses thereof


The present invention relates to antibodies against human csf-1r (csf-1r antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.. .
Hoffmann-la Roche Inc.
06/25/15
20150175695
new patent

Rac1 inhibitors for the treatment of alport glomerular disease


The present invention provides methods of treating alport syndrome in a subject by the administration of an agent that can blocks the activation of rac1/cdc42 members of the rho family of small gtpases. Such agents include, but are not limited to, the endothelin receptor antagonists such as bosentan and letairis and neutralizing antibodies to endothelin-1.
Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital
06/25/15
20150175694
new patent

Dual specificity antibodies and methods of making and using


antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies.
Abbvie Inc.
06/25/15
20150175693
new patent

Novel il-3 antibodies and their use in diagnosis and treatment of diseases or malfunctions associated with elevated levels of il-3


Novel anti-il-3 antibodies or fragments or constructs thereof according to the present invention specifically bind to an epitope contained within the n-terminal 20 amino acids of the amino acid sequence of human il-3 according to seq id no. 1, and preferably to a sequence motif swvn.
Universitatsklinikum Regensburg
06/25/15
20150175692
new patent

Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders


The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine il-17a. The disclosure more specifically relates to specific antibodies and proteins that are il-17a antagonists (inhibit the activities of il-17a and il-17af) and are capable of inhibiting il-17a induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo.
Novartis Ag
06/25/15
20150175691
new patent

Methods of administering anti-tnfalpha antibodies


Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
Abbvie Biotechnology Ltd.
06/25/15
20150175690
new patent

Multiple-variable dose regimen for treating tnfalpha-related disorders


Multiple-variable dose methods for treating tnfα-related disorders, including crohn's disease and psoriasis, comprising administering tnfα inhibitors, including tnfα antibodies, are described. Multiple-variable dose methods include administration of a tnf-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the tnf-inhibitor is administered in a higher dosage during the induction phase..
Abbvie Biotechnology Ltd
06/25/15
20150175689
new patent

Anti-vegf antibodies


Anti-vegf antibodies and variants thereof, including those having high affinity for binding to vegf, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-vegf antibodies with desired binding and other biological activities.
Genentech, Inc.
06/25/15
20150175688
new patent

Production cell line enhancers


The present invention relates to discovery of the ectopic expression of edem2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the cho cell, containing recombinant polynucleotides encoding edem2.
Regeneron Pharmaceuticals, Inc.
06/25/15
20150175686
new patent

Monoclonal antibodies for treatment of cancer


The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing gt468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.. .
Johannes Gutenberg-universitat Mainz
06/25/15
20150175685
new patent

Humanized anti-tau(ps422) antibodies and methods of use


The invention provides humanized anti-human tau(ps422) antibodies and methods of using the same.. .
Hoffmann-la Roche Inc.
06/25/15
20150175684
new patent

Abeta conformer selective anti-abeta globulomer monoclonal antibodies


The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of alzheimer's disease. In particular, the present invention relates to monoclonal antibodies referred to as 10f4 and 3c5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto..
Abbvie Inc.
06/25/15
20150175682
new patent

Humanized tau antibody


The present invention provides, methods end composites for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to humanized antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers to methods and compositions involving antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including alzheimer's disease (ad)..
Genentech, Inc.
06/25/15
20150175681
new patent

Antibodies for the treatment of clostridium difficile-associated infection and disease


Provided herein are reagents, compositions, and therapies with which to treat clostridium difficile infection and related disease conditions and pathologies, such as clostridium difficile-associated diarrhea, resulting from infection by clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin a and/or toxin b of c difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided..
Progenics Pharmaceuticals, Inc.
06/25/15
20150175680
new patent

Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse


The invention described herein provides for human antibodies produced in non-human animals that specifically bind to pseudomanas aeruginosa lipopolysaccharide (lps). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems.
Case Western Reserve University
06/25/15
20150175679
new patent

Hiv-1 peptides, nucleic acids, and compositions, and uses thereof


This invention features polypeptides, variants thereof, and fragments thereof useful in eliciting an immune response (e.g., neutralizing antibodies) against a broad spectrum of hiv-1 isolates. The polypeptides, variants, and fragments include a portion of the gp120 v2 domain of hiv-1.
Rutgers, The State University Of New Jersey
06/25/15
20150175678
new patent

Iga cd4i antibodies and methods of treatment using same


The present invention relates to isolated iga antibodies, or fragments thereof, which have variable domains derived from an antibody that specifically binds to a cd4-induced (cd4i) epitope. In particular, the isolated iga antibodies display enhanced neutralization activity relative to their igg, non-chimeric counterparts.
Beth Israel Deaconess Medical Center, Inc.
06/25/15
20150174242
new patent

Monovalent anti-cd3 adjuvants


This document provides methods and materials related to using monovalent anti-cd3 antibodies (e.g., monovalent anti-cd3 fab fragments) as adjuvants to increase the immune response produced against an antigen (e.g., a tumor associated antigen). For example, vaccine compositions containing monovalent anti-cd3γε fab fragments in combination with tumor associated antigens (e.g., tumor associated antigens having little or no immunogenicity in the absence of monovalent anti-cd3γε fab fragments) alone or in combination with adjuvants for signals two and/or three required for full activation of t cell immune function, as well as methods and materials for using monovalent anti-cd3γε fab fragments to increase the immune response produced against an antigen (e.g., a tumor associated antigen) within a mammal (e.g., a human) are provided..
Mayo Foundation For Medical Education And Research
06/25/15
20150174226
new patent

Ompa and asp14 in vaccine compositions and as diagnostic targets


Anaplasma phagocytophilum surface proteins asp14 and ompa and homologous genes from anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Asp14 and/or ompa proteins or peptide fragments may be used in combination with other anaplasmatacaea surface proteins to elicit an immune response.
Virginia Commonwealth University
06/25/15
20150174224
new patent

Materials and methods for eliciting targeted antibody responses in vivo


Methods for generating and identifying antibodies specifically binding target molecules expressed by cells embedded in a three-dimensional extracellular matrix resembling the in vivo environment and form of the target are provided. Also provided are methods of producing immunogens that yield targets in such forms.
The Regents Of The University Of Michigan
06/25/15
20150173332
new patent

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.
06/25/15
20150173331
new patent

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.
06/18/15
20150168402

Novel immunogenic proteins of leptospira


The invention provides novel immunogenic proteins liga and ligb from leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.. .
Cornell University
06/18/15
20150168399

Marker peptides for determining the occurrence of an inflammatory state in a subject


An enzyme proteolysis-resistant peptide that binds to antibodies directed against the amino acid region 1-116 of the endocan's polypeptide sequence, which peptide possesses an apparent molecular weight of 14 kda.. .
Institut Pasteur De Lille
06/18/15
20150167078

Methods for antibody and cell therapeutic discovery


A method is provided for discovering antibodies with desired properties. In one aspect of this invention, oligoclonal single chain repertoires are determined in a target tissue.
Gigagen, Inc.
06/18/15
20150166680

Highly diverse combinatorial anitbody libraries


Disclosed is an immune library obtained from a camelid species containing at antibody chains belonging to at least 7 human germline antibody chains. The presence of a large number of human germline antibody chain families in the library contributes to the usefulness of the library in producing antibodies to human target antigens.
Argen-x N.v.
06/18/15
20150166678

Compositions and methods comprising binding proteins for adalimumab


Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine tnf-α and was developed to treat tnf-α mediated inflammatory diseases.
Abbvie Biotechnology Ltd
06/18/15
20150166674

Antibodies and immunoconjugates and uses therefor


Anti-steap-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-steap-1 antibodies and immunoconjugates thereof are provided..
Genentech, Inc.
06/18/15
20150166670

Multispecific antibodies


The present invention relates to bivalent, multispecific antibodies, especially bivalent, trispecific antibodies which bind to human her1, human her2, and human her3, their manufacture and use.. .
Hoffmann-la Roche Inc.
06/18/15
20150166669

Anti-cd74 immunoconjugates and methods of use


Disclosed are compositions that include anti-cd74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-cd74 antibodies or antigen-binding fragments thereof, conjugated to a carrier such as a polymer, nanoparticle, complex or micelle.
Immunomedics, Inc.
06/18/15
20150166668

Antibodies and conjugates that target misfolded prion protein


Human prion protein, prp, selectively presents the epitope mdeysnqnn (seq id no. 14) when prp misfolds.
Helix Biopharma Corp.
06/18/15
20150166664

Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation


The present invention pertains to the field of cancer therapy using anti-cancer antibodies. The medical use of anti-her2 antibodies having improved glycosylation characteristics, in particular a reduced fucosylation, is provided which show enhanced efficacy..
Glycotope Gmbh
06/18/15
20150166663

Antibodies directed to alpha v beta 6 and uses thereof


Targeted binding agents, such antibodies directed to the antigen αvβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αvβ6 are disclosed.
Medimmune Limited
06/18/15
20150166662

Glycan-modified anti-cd4 antibodies for hiv prevention and therapy


Disclosed herein are glycan-modified anti-cd4 monoclonal antibodies with n-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for hiv prevention and therapy are also disclosed..
06/18/15
20150166661

Anti-cd3 antibodies and methods of use


The invention provides anti-cluster of differentiation 3 (cd3) antibodies and methods of using the same.. .
Genentech, Inc.
06/18/15
20150166659

Humanized l243 antibodies


Humanized antibodies are provided that specifically bind hla-dr. The antibodies recognize the epitope recognized by the murine monoclonal antibody l243.
Immunomedics, Inc.
06/18/15
20150166658

Bcr-complex-specific antibodies and methods of using same


This invention relates to chimeric and humanized antibodies that specifically bind the bcr complex, and particularly chimeric and humanized antibodies to the bcr complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.
06/18/15
20150166656

Monoclonal antibodies to gastrin hormone


The present invention provides monoclonal antibodies (mabs) selective for the n-termini and c-termini of the gastrin hormone forms, gastrin-17 (g17), glycine-extended gastrin-17 (g17-gly), gastrin-34 (g34) and glycine-extended gastrin-34 (g34-gly); and the hybridomas that produce these mabs. Also provided are panels of mabs useful for the detection and quantitation of gastrin-17 (g17), glycine-extended gastrin-17 (g17-gly), gastrin-34 (g34) and glycine-extended gastrin-34 (g34-gly).
Cancer Advances Inc.
06/18/15
20150166655

Anti-interferon alpha monoclonal antibodies and methods of use


The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“ifnα”) protein subtypes for the protein subtypes a, 2, b2, c, f, g, h2, i, j1, k, 4a, 4b and wa, but does not neutralize at least one bioactivity of ifnα protein subtype d. Examples of bioactivity for measurement include activation of the m×a promoter or antiviral activity and variants, derivatives and fragments thereof.
Baylor Research Institute
06/18/15
20150166648

Compositions and methods for crystallizing antibodies


The present invention relates to a batch crystallization method for crystallizing anti-human tnfalpha (htnfalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-htnfalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions.. .
Abbvie Inc.
06/18/15
20150166647

Antikine antibodies that bind to multiple cc chemokines


An antikine antibody binds to two, three, four, five or more cc chemokines, such as rantes/ccl5, mip-1α/ccl3, mip-1β/ccl4, or mcp-1/ccl2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed..
Regeneron Pharmaceuticals, Inc.
06/18/15
20150166643

Humaneered anti-factor b antibody


This invention relates to humaneered anti-factor b antibodies and antigen-binding fragments thereof with modified glycosylation patterns. The humaneered anti-factor b antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor b in the third short consensus repeat (“scr”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the c3bbb complex.
Alexion Pharmaceuticals, Inc.
06/18/15
20150166641

Compositions and methods for the removal of biofilms


This invention provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm.
Research Institute At Nationwide Children's Hospital
06/18/15
20150166640

Immunoglobulins and variants directed against pathogenic microbes


Anti-microbial monoclonal antibodies and variant antibodies having a heavy chain constant regions with at least one amino acid substitution are provided. Such antibodies may be used to prevent or treat microbial infections..
06/18/15
20150166631

Anti-pro87299 antibodies


The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease.. .
Genentech, Inc.
06/18/15
20150166630

Btnl3 proteins, nucleic acids, and antibodies and uses thereof


The invention provides novel btnl3 proteins, including multimers, fragments, fusion proteins, and variants. In addition, antibodies that can bind to btnl3 proteins and nucleic acids encoding btnl3 proteins are provided.
Amgen Inc.
06/18/15
20150165076

Anti-mucin antibodies for early detection and treatment of pancreatic cancer


Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human pam4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers.
Immunomedics, Inc.
06/18/15
20150165064

Enzymatic conjugation of polypeptides


The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions..
Paul Scherrer Institut
06/18/15
20150165025

Methods for treating cancer using anti-pd-1 antibodies


The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Ono Pharmaceutical Co., Ltd.
06/18/15
20150165023

Methods of administering anti-tnfalpha antibodies


Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
Abbvie Biotechnology Ltd.
06/18/15
20150165022

Antibodies against amyloid beta 4 with glycosylation in the variable region


The present invention relates to a purified antibody molecule preparation being characterized in that at least one antigen binding site comprises a glycosylated asparagine (asn) in the variable region of the heavy chain (vh). More specifically, a pharmaceutical and a diagnostic composition comprising said antibody molecule and antibody mixtures are provided which is/are capable of specifically recognizing the β-a4 peptide/aβ4.
Hoffmann-la Roche Inc.
06/18/15
20150165016

Polysaccharide compositions and methods of use


The invention relates, in part, to the use of compositions of poly n-acetylated glucosamine (pnag) and antibodies specific to pnag in the prevention and treatment of infections by certain pnag-positive pathogens and in detection (including diagnostic) methods.. .
The Brigham And Women's Hospital, Inc.
06/18/15
20150165015

Use of alpha-toxin for treating and preventing staphylococcus infections


Vaccines comprising an s. Aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections.
Glaxosmithkline Biologicals S.a.
06/18/15
20150165014

Mycobacterial antigen vaccine


The present invention relates generally to immunogenic combinations comprising at least five antigens of a mycobacterium species as well as fusion thereof and nucleic acid molecules encoding such combined antigens and fusion. The present invention also relates to nucleic acid molecules, vectors, host cells and compositions comprising or encoding said combinations of mycobacterial antigens and fusion polypeptides as well as to methods for recombinantly producing them.
Transgene Sa
06/11/15
20150160235

Anti-mif immunohistochemistry


The present invention pertains to the specific detection of mif, in particular oxmif, in tissues. A detection method is provided which uses immunohistochemistry and wherein specific anfi-oxmif antibodies are used..
Baxter International Inc.
06/11/15
20150160226

Method, reagents, and kits for detecting minimal residual disease


The invention relates to the field of minimal residual disease (mrd) diagnostics, which is progressively more applied for the evaluation of treatment effectiveness in patients with a hematological malignancy, such as b-cell precursor acute lymphoblastic leukemia (bcp-all), b-cell chronic lymphocytic leukemia (b-cll), and multiple myeloma (mm). Provided are unique reagent compositions with carefully selected and thoroughly tested combinations of antibodies, for ≧8-color flow cytometric stainings as well as for 10-color and 12-color flow cytometric stainings, which can reach sensitivities of at least 10−4, even down to 10−5.
Erasmus University Medical Center Rotterdam
06/11/15
20150160217

Glycan arrays for high throughput screening of viruses


Glycan arrays that can detect and distinguish between various sub-types and strains of influenza virus are provided. Methods for using the glycan arrays with assays using nanoparticle amplification technique are disclosed.
Academia Sinica
06/11/15
20150160206

Microfluidic device and testing the same


Provided is a microfluidic device that is capable of rapidly performing an in vitro diagnosis and being miniaturized. The microfluidic device includes: a platform which includes a sample injection hole through which a sample may be injected; and a chamber which is formed in the platform and in which a first reagent, which includes target antigens that exist in the sample and antibodies that are specifically combined with the target antigens, and a second reagent, which includes an antigen-enzyme conjugant in which antigens that are specifically combined with the antibodies and enzymes are conjugated, are stored..
Samsung Electronics Co., Ltd.
06/11/15
20150160192

Antibody-binding protein-drug conjugate and methods of use


The present invention provides compositions and methods for preparing protein drug conjugate and its application to stem cell therapy and treating cancer cells. The composition is an antibody-binding-therapeutic drug conjugate that binds antibodies targeted to cancer or stem cells.


Popular terms: [SEARCH]

Antibodies topics: Antibodies, Recombinant, Nucleic Acid, Nucleic Acids, Polypeptide, Therapeutics, Immunoglobulin, Immunoglobulins, Monoclonal, Radiation Therapy, Desmoplastic, Hypertension, Hypertensive, Immunotherapy, Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.7598

3447

0 - 1 - 75